Prevalence of metabolic syndrome according to NCEP-ATP III and IDF criteria in patients on hemodialysis.
Metabolic syndrome (MS) has a high prevalence in hemodialysis' patients and is a risk factor for cardiovascular disease, the leading cause of mortality in chronic kidney disease (CKD). Objectives To evaluate the prevalence of MS in patients on hemodialysis (HD) and the difference in its prevalence according to the NCEP-ATP III and IDF criteria. We evaluated HD patients in two outpatient clinics in Fortaleza, with dialysis vintage of at least 3 months and aged 18 + years. The patients underwent measurement of waist circumference, blood pressure (BP), dosages of glucose, triglycerides and HDL-cholesterol in fasting. 115 patients were included and the prevalence of MS was 41.7% according to the NCEP-ATP III and 42.6% according to the IDF. Among the 48 patients with a diagnosis of MS according to the NCEPATP III, 87.5% were diagnosed by the IDF. Among the 67 patients without MS by NCEP-ATP III, 89.5% were not diagnosed by means of the IDF. The variables of MS according to the NCEP which had a higher prevalence were abnormal HDL-chol in 83.4% of patients and BP altered or use of antihypertensive drugs in 81.3%. The prevalence of MS in the study population was high, regardless of the criteria used. The variables that contributed most to the diagnosis of MS were dyslipidemia and blood pressure. Routine assessment of the diagnosis of MS in HD should be implemented, since patients with MS have an increase in the number of hospitalizations and in the risk of cardiovascular events.